Form 4: Myriad Genetics Director Daniel Skovronsky Acquires Nearly 50,000 Restricted Stock Units

Myriad Genetics, Inc. Director Daniel Skovronsky has acquired 49,796 shares of common stock in the form of restricted stock units, as disclosed in a recent SEC Form 4 filing.

Summary

• Daniel Skovronsky, a Director at Myriad Genetics Inc. (MYGN), acquired 49,796 shares of common stock on June 5, 2025.
• The acquisition was in the form of Restricted Stock Units (RSUs) at a price of $0 per share.
• These RSUs were granted under Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended.
• Each RSU represents a contingent right to receive one share of common stock.
• The RSUs are set to vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant.
• Following this transaction, Daniel Skovronsky beneficially owns a total of 135,806 shares of common stock.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by a director is generally viewed positively as it aligns the director's financial interests with the long-term performance of the company, indicating confidence and commitment.

Positives

• The acquisition of 49,796 restricted stock units by a director aligns management's interests with those of shareholders, as the value of these units is tied to the company's stock performance.
• The grant is part of an existing equity incentive plan, indicating a structured approach to executive and director compensation aimed at long-term retention and motivation.

Future Outlook

The acquired Restricted Stock Units are subject to a vesting schedule, which will occur upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant, indicating future share issuance to the director.

Industry Context

The granting of Restricted Stock Units (RSUs) to directors is a common practice in the biotechnology and healthcare sectors, aligning the interests of leadership with long-term shareholder value creation. This type of equity compensation is a standard component of executive and director remuneration packages across various industries.

Corporate Governance

Related Party Transactions

• The transaction involves the company granting equity compensation (Restricted Stock Units) to a director, Daniel Skovronsky, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, as the value of the compensation is directly tied to the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees/Directors: This transaction demonstrates the company's commitment to its equity incentive plan, which can serve as a model for other employees and directors regarding long-term compensation and retention.

Next Steps

• The Restricted Stock Units will vest upon the earlier of the first anniversary of the grant date (June 5, 2026) or the date of the next annual meeting of stockholders following the grant.

Key Dates

Keywords

Myriad Genetics, MYGN, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Equity Incentive Plan, Beneficial Ownership, Biotechnology, Genetics, Healthcare